Xsensio closes a $7M oversubscribed Series A and starts a long-term collaboration with Texas Instruments.Read the announcement

Illustrative visualisation. Not the exact device and not clinical data.

Continuous biochemical insight, read directly from the skin

The Lab-on-Skin™ chip, born at the EPFL Nanolab, tracks inflammation and other critical biomarkers in real time, from the ICU to outpatient care and the home.

Explore the technology
  1. Proprietary skin interfaceInterstitial fluid, the body's natural window into inflammation, metabolism and organ function, reaches the chip.
  2. Semiconductor sensingA highly miniaturised multi-sensor chip reads metabolites, ions, proteins and hormones together.
  3. Wireless, in real timeData reaches patients, caregivers or healthcare providers, on demand or continuously.

How the Lab-on-Skin™ system works

Every Xsensio solution is built on the same core system, then tailored to the clinical or wellness question it has to answer.

1Engineer in a cleanroom suit holding a silicon wafer with rows of sensor chips

Customised multi-sensor chip

Semiconductor sensors give high sensitivity at extreme miniaturisation, with several biomarkers on one die.

2A small square Xsensio sensor chip balanced on a fingertip

Proprietary skin interface

Brings interstitial fluid to the sensors, so readings come from the body's internal state, not from the surface.

3

Wireless communication

On-demand or continuous data streaming, made securely available in real time.

4Xsensio Lab-on-Skin solution overview showing a phone app with a risk alert next to the wearable unit

Data analytics tool

Developed per application, independently or with partners, to turn raw sensor data into actionable insight.

One chip, configured for each clinical question

Depending on the use case, the Lab-on-Skin™ chip carries a specific set of biochemical sensors. The first product focuses on early detection of organ dysfunction.

Continuous tracking where earlier detection of clinical deterioration changes how and when care decisions are made.

Metabolites Ions Proteins Hormones
Illustrative layouts. Actual sensor sets are defined per programme.
Scientist working at an instrument in a laboratory lit in blue and purple

Born at the EPFL Nanolab, at the crossroads of nanotech and biochemistry

The sensing platform was developed at the Nanolab of the Swiss Federal Institute of Technology in Lausanne. Nanotechnology, biochemistry and microfluidics come together to detect subtle physiological changes as they happen.

350+international articles published by co-founder Prof. Adrian Ionescu
10patent families, own and exclusively licensed from EPFL

Scientists, engineers and builders

Xsensio aims to become the leading company in wearable systems that continuously monitor our physiological state to detect risks in real time.

Esmeralda Megally

CEO & Co-Founder

MBA from MIT. Previously a manager at Boston-based investment firm Commons Capital.

Prof. Adrian Ionescu

CTO & Co-Founder

Full Professor at EPFL, where he leads the Nanolab.

Ali Saeidi, PhD

Director of Product Development

PhD in micro and nanoelectronics from the Swiss Federal Institute of Technology.

Johan Longo, PhD

Head of Chemistry

Builds the library of biochemical applications for the platform.

Work with Xsensio

Hospitals and clinical researchers

Critical care, oncology and surgical teams exploring continuous biochemical monitoring with Xsensio.

Discuss a collaboration

Industry and technology partners

Medtech, semiconductor and wellness companies building on the Lab-on-Skin™ platform.

Talk partnerships

Press and investors

Announcements, media assets and company background.

Contact press